Compare BridgeBio Pharma Inc (BBIO) vs Equinix Inc (EQIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Equinix Inc — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.46B), while Equinix Inc trades at $1,024.21 (market cap $100.95B). The key difference: Equinix Inc is far larger — about 6.1× BridgeBio Pharma Inc's market cap, and Equinix Inc pays a 1.92% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | EQIX | |
|---|---|---|
Market Cap | $16.46B | $100.95B |
Sector | Health | Real Estate |
52-Week High | $90.17 | $1.12K |
52-Week Low | $44.81 | $726.09 |
Enterprise Value | $18.02B | $121.23B |
Dividend Yield | — | 1.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
EQIX trades at $1,039.53, down 1.11% on the day, with a bullish technical signal and strong analyst support (74.51% buy ratings). Revenue grew to $9.22B in 2025, with net income reaching $1.35B, though recent quarters showed mixed earnings results. The company benefits from AI infrastructure demand, evidenced by partnerships with Cisco and NVIDIA (Business Wire, 2026-06-17).
Outlook remains positive due to recurring revenue growth and AI tailwinds, but high valuation (P/E 71.89) and negative cash flow (-$1.26B in 2025) pose risks. Debt levels are rising, with debt-to-asset ratio at 47.13% in 2025. The consensus price target of $1,110 suggests upside potential if execution aligns with AI-driven demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →
